Applications

SiCare Bio is partnering with the pharma industry to develop and deliver novel drug delivery mechanisms

Targeted Delivery: Redosable delivery of payloads direct to cells. Click on image for more detail.

Extended-Release Delivery: Sustained delivery of payloads both locally and systemically. Click image for more detail.

Targeted Delivery:

SiCare Bio offers the targeted delivery of biologic or small molecule constructs including siRNA, mRNA, antibodies and chemotherapeutics through its nanoporous silicon dioxide (nPSi) nanoparticles.

Our nPSi nanoparticles are engineered to address the shortcomings of lipid nanoparticle (LNP) drug delivery systems by offering a:

  • Tunable pores to protect the RNA payload prior to its release
  • Low-toxicity in vivo dissolution pathway
  • High loading capacity for nucleic acid payloads
  • Direct cytosolic release into the cells, avoiding endocytosis

Extended Release Delivery:

For extended-release drug delivery, nanoporous silicon dioxide (nPSi) microparticles are utilized. In this application, the nanopores in the particles are filled active pharmaceutical ingredient and released as the particles are broken down in the body. pSiMPs have several advantages over traditional, polymer-based drug delivery systems, including:

  • Improved Tolerability: Silicon completely degrades into orthosilicic acid, a naturally occurring silicon found in the body without accumulation or residue
  • Release Profile: nPSi particles are custom engineered to accommodate specific drugs and pre-determined release profiles. As such nPSi particles do not face the “burst” release profile associated with traditional polymer-based drug delivery systems.
  • Therapeutic Compatibility: Polymers are cast from organic solvents that are often not compatible with proteins. The nPSi drug loading process is aqueous based and as such can accommodate a broader range of payloads.